Double-Blind Placebo-Controlled Pilot Investigation of the Safety of a Single Dose of Rapid-Acting Intranasal Insulin in Down Syndrome

ConclusionsFurther investigations are necessary to better evaluate the potential cognitive-enhancing role of intranasal insulin in the Down syndrome population.ClinicalTrials.gov IDNCT02432716.

Source: Drugs in R&D - February 18, 2020 Category: Drugs & Pharmacology Source Type: research